Guerra Ugo Paolo, Nobili Flavio Mariano, Padovani Alessandro, Perani Daniela, Pupi Alberto, Sorbi Sandro, Trabucchi Marco
Nuclear Medicine, Fondazione Poliambulanza, Istituto Ospedaliero, Brescia, Italy.
Neurol Sci. 2015 Jun;36(6):1075-81. doi: 10.1007/s10072-015-2079-3.
Positron emission tomography (PET) of brain amyloid is a technology that has been approved by Food and Drug Administration and European Medical Agency, but its clinical utility in medical practice requires careful definition. To provide guidance to italian dementia care practitioners, patients, and caregivers, a group of experts from "Associazione Italiana di Medicina Nucleare" (AIMN), "Associazione Italiana di Psicogeriatria" (AIP) and "Società Italiana per lo Studio delle Demenze" (SINDEM) convened the Italian Interdisciplinary Working Group on Amyloid Imaging. The Working Group considered a range of clinical scenarios in which amyloid PET should be recommended. Peer-reviewed, published literature was searched to ascertain available evidence relevant to these recommendations. Although empirical evidence of impact on clinical outcomes is not yet available, a set of specific recommended use criteria were agreed to define the types of patients and clinical circumstances in which amyloid PET could be used. Both correct and incorrect uses were considered and formulated. Because both dementia care and amyloid-PET technology are in active development, these recommendations will require periodic reassessment.
脑淀粉样蛋白正电子发射断层扫描（PET）是一项已获美国食品药品监督管理局和欧洲药品管理局批准的技术，但其在医疗实践中的临床应用需要仔细界定。为了给意大利痴呆症护理从业者、患者及护理人员提供指导，来自“意大利核医学协会”（AIMN）、“意大利老年精神病学协会”（AIP）和“意大利痴呆症研究协会”（SINDEM）的一组专家召集了意大利淀粉样蛋白成像跨学科工作组。该工作组考虑了一系列应推荐使用淀粉样蛋白PET的临床情况。通过检索同行评审的已发表文献来确定与这些建议相关的现有证据。尽管尚未获得关于对临床结果影响的实证证据，但已商定了一套具体的推荐使用标准，以界定可使用淀粉样蛋白PET的患者类型和临床情况。同时考虑并制定了正确和不正确的使用方法。由于痴呆症护理和淀粉样蛋白PET技术都在不断发展，这些建议需要定期重新评估。
